Complement C1 inhibitor protein - Shire

Drug Profile

Complement C1 inhibitor protein - Shire

Alternative Names: C1 esterase inhibitor - Baxter Healthcare; C1 esterase inhibitor - Hyland Immuno; C1 esterase inhibitor - Shire; C1 Inattivatore Umano; C1 inhibitor - Hyland Immuno; C1 inhibitor - Shire; Complement C1 esterase inhibitor - Baxter Healthcare; Complement C1 esterase inhibitor - Hyland Immuno; Complement C1 esterase inhibitor - Shire

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International
  • Developer Baxalta; Hyland Immuno
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angioedema
  • Discontinued Pancreatic disorders; Transplant rejection

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 16 Feb 2016 Biomarkers information updated
  • 19 Apr 2002 No development reported - Clinical-Phase-Unknown for Angioneurotic oedema in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top